Karl Skriner Selected Research

Heterogeneous-Nuclear Ribonucleoproteins (Informatin)

1/2021	The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.
5/2011	Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis.
8/2009	Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement.
2/2008	AUF1, the regulator of tumor necrosis factor alpha messenger RNA decay, is targeted by autoantibodies of patients with systemic rheumatic diseases.
1/2006	The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus.
7/2002	Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karl Skriner Research Topics

Disease

18	Rheumatoid Arthritis 11/2022 - 03/2002
6	Arthritis (Polyarthritis) 12/2018 - 03/2005
5	Autoimmune Diseases (Autoimmune Disease) 01/2018 - 03/2002
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2011 - 03/2002
3	Inflammation (Inflammations) 01/2018 - 03/2005
2	COVID-19 11/2020 - 08/2020
2	Weight Loss (Weight Reduction) 11/2020 - 08/2020
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2022
1	Pain (Aches) 01/2021
1	Stroke (Strokes) 10/2020
1	Acute Coronary Syndrome 10/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2020
1	Lung Diseases (Lung Disease) 01/2020
1	Infections 01/2020
1	Systemic Scleroderma (Systemic Sclerosis) 08/2009
1	Mixed Connective Tissue Disease (MCTD) 02/2008
1	Rheumatic Diseases (Rheumatism) 02/2008

Drug/Important Bio-Agent (IBA)

12	AutoantibodiesIBA 01/2021 - 03/2002
9	AutoantigensIBA 01/2020 - 03/2002
7	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2008
6	Anti-Citrullinated Protein AntibodiesIBA 11/2022 - 01/2018
6	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 01/2021 - 07/2002
5	Peptides (Polypeptides)IBA 01/2020 - 12/2005
4	EpitopesIBA 11/2020 - 01/2018
4	acetyl 4-aminosalicylic acidIBA 10/2020 - 12/2018
3	Monoclonal AntibodiesIBA 11/2020 - 01/2019
3	AntibodiesIBA 01/2019 - 01/2018
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2008 - 03/2005
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2018
2	Neutralizing AntibodiesIBA 11/2020 - 08/2020
2	CV07-209IBA 11/2020 - 08/2020
2	Rheumatoid FactorIBA 10/2020 - 01/2020
2	Immunoglobulin M (IgM)IBA 01/2020 - 12/2007
2	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2018 - 01/2006
2	AntigensIBA 05/2011 - 01/2004
2	pristane (pristan)IBA 05/2011 - 12/2007
2	Immunoglobulin G (IgG)IBA 12/2007 - 12/2005
1	Etanercept (Enbrel)FDA Link 01/2021
1	omega-Chloroacetophenone (Mace)IBA 10/2020
1	cyclic citrullinated peptideIBA 01/2020
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 01/2020
1	CitrullineIBA 12/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2018
1	HLA-DRB1 Chains (HLA DRB1)IBA 01/2018
1	hnRNP A2IBA 05/2011
1	Nucleic AcidsIBA 05/2011
1	Messenger RNA (mRNA)IBA 02/2008
1	Mineral Oil (Liquid Paraffin)FDA LinkGeneric 12/2007
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 12/2005
1	Filaggrin ProteinsIBA 07/2002

Therapy/Procedure

1	Intradermal Injections 12/2007
1	Therapeutics 01/2004